Connor Clark & Lunn Investment Management Ltd. Has $2.05 Million Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 31.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 932,008 shares of the biopharmaceutical company's stock after buying an additional 220,730 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.47% of Esperion Therapeutics worth $2,050,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio bought a new position in Esperion Therapeutics in the 3rd quarter worth approximately $606,000. Anson Funds Management LP acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $540,000. Wellington Management Group LLP grew its holdings in shares of Esperion Therapeutics by 66.8% during the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company's stock worth $995,000 after purchasing an additional 241,512 shares in the last quarter. Wasatch Advisors LP grew its holdings in shares of Esperion Therapeutics by 38.4% during the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock worth $38,521,000 after purchasing an additional 6,483,070 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Esperion Therapeutics by 99.6% during the 3rd quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company's stock worth $510,000 after purchasing an additional 154,509 shares in the last quarter. 47.39% of the stock is owned by institutional investors.

Remove Ads

Esperion Therapeutics Trading Up 4.3 %

ESPR stock traded up $0.07 during trading on Friday, hitting $1.69. The company had a trading volume of 5,003,722 shares, compared to its average volume of 5,966,927. The company has a fifty day moving average price of $1.84 and a two-hundred day moving average price of $2.07. The company has a market cap of $334.36 million, a P/E ratio of -2.64 and a beta of 1.04. Esperion Therapeutics, Inc. has a fifty-two week low of $1.47 and a fifty-two week high of $3.94.

Wall Street Analysts Forecast Growth

ESPR has been the topic of several recent research reports. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They set an "overweight" rating and a $8.00 price objective on the stock. Needham & Company LLC reissued a "buy" rating and set a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. JMP Securities reissued a "market outperform" rating and set a $4.00 price objective (down previously from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a "neutral" rating and a $4.00 price target on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $6.75.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.